Mantle-cell lymphoma (MCL) with relapsed/refractory (R/R) disease after intensive chemotherapy have few effective treatment options. Ibrutinib showed a promising median progression-free survival (PFS) with manageable toxicity. The BCL2 inhibitor venetoclax showed encouraging results in R/R MCL patients and preclinical models suggest a potential synergistic effect of dual BTK and BCL2 inhibition. Ibrutinib in association with venetoclax was successfully investigated in a phase II trial.
Fabbri, A., Cencini, E., Congiu, A.G., Miglino, M., Rigacci, L., Bocchia, M. (2020). Ibrutinib in association with venetoclax for the treatment of mantle-cell lymphoma: a multicenter case series. AMERICAN JOURNAL OF BLOOD RESEARCH, 10(6), 355-359.
Ibrutinib in association with venetoclax for the treatment of mantle-cell lymphoma: a multicenter case series
Fabbri, Alberto
Conceptualization
;Cencini, Emanuele;Bocchia, Monica
2020-01-01
Abstract
Mantle-cell lymphoma (MCL) with relapsed/refractory (R/R) disease after intensive chemotherapy have few effective treatment options. Ibrutinib showed a promising median progression-free survival (PFS) with manageable toxicity. The BCL2 inhibitor venetoclax showed encouraging results in R/R MCL patients and preclinical models suggest a potential synergistic effect of dual BTK and BCL2 inhibition. Ibrutinib in association with venetoclax was successfully investigated in a phase II trial.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
https://hdl.handle.net/11365/1147012
Attenzione
Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo